Education
About Us
Working with TipRanks
Follow Us
Silexion Therapeutics (SLXN)
NASDAQ:SLXN
RESEARCH TOOLSreports
Total Valuation
Silexion Therapeutics has a market cap or net worth of $9.04M. The enterprise value is ―.
Market Cap$9.04M
Enterprise Value―
Share Statistics
Silexion Therapeutics has 8,692,392 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,692,392
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Silexion Therapeutics’s return on equity (ROE) is -8.25K and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-8.25K
Return on Assets (ROA)5.77
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.50M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Silexion Therapeutics is 0.99. Silexion Therapeutics’s PEG ratio is ―.
PE Ratio0.99
PS Ratio0.00
PB Ratio-2.39
Price to Fair Value-8.19K
Price to FCF-1.17
Price to Operating Cash Flow-1.14
PEG Ratio―
Income Statement
In the last 12 months, Silexion Therapeutics had revenue of 0.00 and earned 16.51M in profits. Earnings per share was 2.03.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income16.51M
Net Income16.51M
EBITDA0.00
Earnings Per Share (EPS)2.03
Cash Flow
In the last 12 months, operating cash flow was -8.40M and capital expenditures -22.00K, giving a free cash flow of -8.42M billion.
Operating Cash Flow-8.40M
Free Cash Flow-8.42M
Free Cash Flow per Share-0.97
Dividends & Yields
Silexion Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.09
52-Week Price Change-98.97%
50-Day Moving Average0.97
200-Day Moving Average6.62
Relative Strength Index (RSI)58.29
Average Volume (3m)2.67M
Important Dates
Silexion Therapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 18, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Silexion Therapeutics as a current ratio of 0.64, with Debt / Equity ratio of -112.58%
Current Ratio0.64
Quick Ratio0.64
Debt to Market Cap0.03
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Silexion Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Silexion Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -2.01.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-2.01
EV to Operating Cash Flow-2.01
Balance Sheet
Silexion Therapeutics has $1.19M in cash and marketable securities with $4.49M in debt, giving a net cash position of $3.30M billion.
Cash & Marketable Securities$1.19M
Total Debt$4.49M
Net Cash$3.30M
Net Cash Per Share$0.38
Tangible Book Value Per Share-$0.49
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Silexion Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside380.77% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-73095.97%